Company profile

IRLAB Therapeutics

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 3 of 3 assets
Target & Modality
Mesdopetam (IRL790)No recent activity
Phase 3
D3Small molecule
Parkinson's Disease
Pirepemat (IRL752)
Phase 3
5-HT/norepinephrineSmall molecule
Parkinson's Disease
IRL757
Phase 2
Undisclosed / early pipelineSmall molecule
Parkinson's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.